← Back to All US Stocks

3M Co (MMM) Stock Fundamental Analysis & AI Rating 2026

MMM NYSE Surgical & Medical Instruments & Apparatus DE CIK: 0000066740
Recently Updated • Analysis: Apr 29, 2026 • SEC Data: 2026-03-31
Combined AI Rating
HOLD
75% Confidence
STRONG AGREEMENT
HOLD
72% Conf
HOLD
78% Conf

📊 MMM Key Takeaways

Revenue: $6.0B
Net Margin: 10.8%
Free Cash Flow: $349.0M
Current Ratio: 1.59x
Debt/Equity: 3.34x
EPS: $1.23
AI Rating: HOLD with 72% confidence
3M Co (MMM) receives a HOLD rating with 75% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $6.0B, net profit margin of 10.8%, and return on equity (ROE) of 20.0%, 3M Co demonstrates mixed fundamentals in the Healthcare sector. Below is our complete MMM stock analysis for 2026.

Is 3M Co (MMM) a Good Investment?

Claude

3M exhibits strong operational profitability (23.2% operating margin, 20% ROE) but faces significant headwinds including zero revenue growth, declining EPS (-20.5%), and elevated financial leverage (3.34x D/E) that constrains strategic flexibility. The company generates positive free cash flow ($349M) with manageable interest coverage (13.2x), but weak asset utilization (1.8% ROA) and declining cash conversion suggest efficiency challenges.

ChatGPT

3M’s fundamentals show a still-profitable business with solid operating margins, adequate liquidity, and manageable interest coverage, but growth quality is weak given flat revenue, slightly declining net income, and a sharp EPS drop. Financial strength is also constrained by high leverage and a very small equity base, which makes headline ROE look stronger than the underlying balance sheet quality suggests.

Why Buy 3M Co Stock? MMM Key Strengths

Claude
  • + Strong operating margin of 23.2% demonstrates pricing power and operational efficiency in mature markets
  • + Excellent return on equity of 20% and solid interest coverage ratio of 13.2x indicate current debt is serviceable
  • + Positive free cash flow generation of $349M provides cushion for dividend and debt servicing despite leverage
ChatGPT
  • + Operating margin of 18.6% and net margin of 13.0% indicate the core business remains meaningfully profitable
  • + Liquidity is reasonable with a 1.71x current ratio, 1.33x quick ratio, and $5.24B of cash
  • + Interest coverage of 10.3x suggests current debt servicing is still manageable

MMM Stock Risks: 3M Co Investment Risks

Claude
  • ! Revenue stagnation at 0% YoY growth in latest period signals market maturity and competitive pressure with no organic expansion
  • ! Excessive financial leverage at 3.34x debt-to-equity limits strategic flexibility and increases refinancing risk in higher rate environment
  • ! Declining diluted EPS (-20.5% YoY) despite flat net income and weak FCF margin (5.8%) suggest deteriorating capital efficiency and shareholder value creation
ChatGPT
  • ! Revenue was flat and net income slightly declined, pointing to limited organic growth momentum
  • ! Diluted EPS fell 20.5% year over year, a much weaker trend than net income
  • ! High leverage with 2.68x debt-to-equity and only $4.70B of equity reduces balance sheet flexibility

Key Metrics to Watch

Claude
  • * Revenue growth trajectory and segment performance to assess end-market demand stabilization
  • * Debt reduction progress and D/E ratio trend as deleveraging is critical to financial health
  • * Free cash flow conversion and operating cash flow sustainability given current weak asset utilization
ChatGPT
  • * Free cash flow and operating cash flow conversion versus net income
  • * Revenue growth and debt reduction relative to equity

3M Co (MMM) Financial Metrics & Key Ratios

Revenue
$6.0B
Net Income
$653.0M
EPS (Diluted)
$1.23
Free Cash Flow
$349.0M
Total Assets
$35.4B
Cash Position
$3.7B

💡 AI Analyst Insight

3M Co presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

MMM Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin 23.2%
Net Margin 10.8%
ROE 20.0%
ROA 1.8%
FCF Margin 5.8%

MMM vs Healthcare Sector: How 3M Co Compares

How 3M Co compares to Healthcare sector averages

Net Margin
MMM 10.8%
vs
Sector Avg 12.0%
MMM Sector
ROE
MMM 20.0%
vs
Sector Avg 15.0%
MMM Sector
Current Ratio
MMM 1.6x
vs
Sector Avg 2.0x
MMM Sector
Debt/Equity
MMM 3.3x
vs
Sector Avg 0.6x
MMM Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is 3M Co Stock Overvalued? MMM Valuation Analysis 2026

Based on fundamental analysis, 3M Co has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
20.0%
Sector avg: 15%
Net Profit Margin
10.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
3.34x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

3M Co Balance Sheet: MMM Debt, Cash & Liquidity

Current Ratio
1.59x
Quick Ratio
1.19x
Debt/Equity
3.34x
Debt/Assets
90.7%
Interest Coverage
13.18x
Long-term Debt
$10.9B

MMM Revenue & Earnings Growth: 5-Year Financial Trend

MMM 5-year financial data: Year 2020: Revenue $32.8B, Net Income N/A, EPS N/A. Year 2021: Revenue $35.4B, Net Income $4.5B, EPS $7.72. Year 2022: Revenue $35.4B, Net Income $5.4B, EPS $9.36. Year 2024: Revenue $26.2B, Net Income $5.8B, EPS $10.18. Year 2025: Revenue $24.9B, Net Income -$7.0B, EPS $-12.63.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: 3M Co's revenue has declined by 24% over the 5-year period, indicating business contraction. The most recent EPS of $-12.63 indicates the company is currently unprofitable.

MMM Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
5.8%
Free cash flow / Revenue

MMM Quarterly Earnings & Performance

Quarterly financial performance data for 3M Co including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $6.0B $653.0M $1.23
Q3 2025 $6.3B $834.0M $1.55
Q2 2025 $6.3B $723.0M $1.34
Q1 2025 $6.0B $928.0M $1.67
Q3 2024 $6.3B $1.4B $2.48
Q2 2024 $6.3B $1.1B $2.07
Q2 2021 $7.2B $1.3B $2.25
Q1 2021 $8.1B $1.3B $2.25

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

3M Co Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$574.0M
Cash generated from operations
Stock Buybacks
$2.0B
Shares repurchased (TTM)
Capital Expenditures
$225.0M
Investment in assets
Dividends Paid
$412.0M
Returned to shareholders

MMM SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for 3M Co (CIK: 0000066740)

📋 Recent SEC Filings

Date Form Document Action
Apr 21, 2026 10-Q mmm-20260331.htm View →
Apr 21, 2026 8-K mmm-20260421.htm View →
Apr 9, 2026 4 xslF345X06/form4.xml View →
Apr 2, 2026 4 xslF345X06/form4.xml View →
Mar 25, 2026 DEF 14A mmm-20260324.htm View →

Frequently Asked Questions about MMM

What is the AI rating for MMM?

3M Co (MMM) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are MMM's key strengths?

Claude: Strong operating margin of 23.2% demonstrates pricing power and operational efficiency in mature markets. Excellent return on equity of 20% and solid interest coverage ratio of 13.2x indicate current debt is serviceable. ChatGPT: Operating margin of 18.6% and net margin of 13.0% indicate the core business remains meaningfully profitable. Liquidity is reasonable with a 1.71x current ratio, 1.33x quick ratio, and $5.24B of cash.

What are the risks of investing in MMM?

Claude: Revenue stagnation at 0% YoY growth in latest period signals market maturity and competitive pressure with no organic expansion. Excessive financial leverage at 3.34x debt-to-equity limits strategic flexibility and increases refinancing risk in higher rate environment. ChatGPT: Revenue was flat and net income slightly declined, pointing to limited organic growth momentum. Diluted EPS fell 20.5% year over year, a much weaker trend than net income.

What is MMM's revenue and growth?

3M Co reported revenue of $6.0B.

Does MMM pay dividends?

3M Co pays dividends, with $412.0M distributed to shareholders in the trailing twelve months.

Where can I find MMM SEC filings?

Official SEC filings for 3M Co (CIK: 0000066740) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MMM's EPS?

3M Co has a diluted EPS of $1.23.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MMM a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, 3M Co has a HOLD rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MMM stock overvalued or undervalued?

Valuation metrics for MMM: ROE of 20.0% (sector avg: 15%), net margin of 10.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.

Should I buy MMM stock in 2026?

Our dual AI analysis gives 3M Co a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MMM's free cash flow?

3M Co's operating cash flow is $574.0M, with capital expenditures of $225.0M. FCF margin is 5.8%.

How does MMM compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 10.8% (avg: 12%), ROE 20.0% (avg: 15%), current ratio 1.59 (avg: 2).

Is 3M Co carrying too much debt?

MMM has a debt-to-equity ratio of 3.34x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.59 suggests adequate short-term liquidity.

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% INVA 92% GCT 92% FTNT 92% FSLR 92% FRSH 92% FAST 92%
Sector: All Healthcare Stocks →
Browse: High ROE Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 29, 2026 | Data as of: 2026-03-31 | Powered by Claude AI